This page is an unofficial mirror and is not legal advice. Verify the document against the official source before relying on it.

HB1292-FN: expanding the right to try act to include certain qualifying severe illness and permitting certain regenerative stem cell therapies under the act.

Bill details

Version history, amendments, and roll-call votes were not present in the imported local bill data.

Official links

stitutional Review Board; and (b) "Off-label use" means prescribing an FDA approved drug, biologic, or device for a use not approved for that specific indication consistent with RSA 329:17, VI-b. III. "Physician" means the licensed allopathic or osteopathic physician who is providing medical care or treatment to the[ eligible] patient for the terminal or qualifying severe illness. III-a. “Qualifying

Extraction diagnostics

Related law links

RSA references from bill data

  • 126-Z · amend · effective 2027-01-01

    l and qualifying severe illness. This chapter shall be construed consistently with the general court's stated purpose. 5 New Section; Regenerative Stem Cell Therapies. Amend RSA 126-Z by inserting after section 8 the following new section: 126-Z:9 Regenerative Stem Cell Therapies. I. A physician may perform stem cell therapy that is not approved by the United States Food and Drug Administrati

  • 126-Z:1 · amend · effective 2027-01-01

    lls, tissues, or cellular or tissue-based products, the state will advance regenerative medicine in a manner consistent with the values of this state. 2 Right to Try Act. Amend RSA 126-Z:1 through 126-Z:4 to read as follows: 126-Z:1 Definitions. In this chapter: I. "Eligible facility" means a licensed New Hampshire institution that is operating under a Federalwide Assurance ("FWA") for the Protec

  • 126-Z:3 · reference · effective 2027-01-01

    evice [to eligible patients pursuant to this chapter. A manufacturer may] not approved by the FDA available to patients if the manufacturer and patient satisfy the requirements of RSA 126-Z:3, II. Pursuant to this chapter, a manufacturer may: (a) Provide [an investigational] a drug, biologic, or device to [an eligible] a patient without receiving compensation. (b) Require [an eligible] a patient to pay

  • 126-Z:6 · amend · effective 2027-01-01

    or court for injunctive relief and reasonable attorney's fees against any regulatory or law enforcement authority that violates this chapter. 3 Telehealth Prescreening. Amend RSA 126-Z:6, I to read as follows: I. Notwithstanding any regulation or provision of law to the contrary, any health care provider, while physically located in New Hampshire, may conduct a telehealth prescreening with any patie

  • 126-Z:8 · amend · effective 2027-01-01

    escreening with any patient, in any state or jurisdiction, who has been diagnosed by a physician with a terminal or qualifying severe illness. 4 Statutory Construction. Amend RSA 126-Z:8 to read as follows: 126-Z:8 Statutory Construction. The general court enacts this chapter to promote maximum access by removing barriers in state law and indemnifying those involved in providing potentially life-sav

  • 126-Z:9 · reference · effective 2027-01-01

    ss” means an illness that is both chronic and debilitating. A qualifying severe illness shall include any condition treated with stem cell therapy pursuant to the requirements of RSA 126-Z:9. III-b. "Chronic and debilitating" shall have the same meaning as "severely debilitating" as defined under 21 CFR section 312.81(b). IV. "Remote signing" means the signing of any form, witnessed by a notary publi

  • 151 · reference · effective 2027-01-01

    to this chapter. II. Notwithstanding any provision of law to the contrary, the department of health and human services shall not take action against a facility licensed under RSA 151 based primarily on the institution's participation in the treatment or use of [an investigational] a drug, biologic, or device under this chapter. III. Notwithstanding any provision of law to the contrary, a manufac

  • 329 · reference · effective 2027-01-01

    withstanding any provision of law to the contrary, the board of medicine shall not revoke, fail to renew, or take any other action against a physician's license issued pursuant to RSA 329 based primarily on a physician's recommendation to [an eligible] a patient regarding or prescription for or treatment with [an investigational] a drug, biologic, or device pursuant to this chapter. II. Notwithstandi

  • 329:17 · reference · effective 2027-01-01

    stitutional Review Board; and (b) "Off-label use" means prescribing an FDA approved drug, biologic, or device for a use not approved for that specific indication consistent with RSA 329:17, VI-b. III. "Physician" means the licensed allopathic or osteopathic physician who is providing medical care or treatment to the[ eligible] patient for the terminal or qualifying severe illness. III-a. “Qualifying

RSAs mentioned by this document